Increasing single epirubicin doses in advanced soft tissue sarcomas

Area of Science:

• Oncology
• Pharmacology

Background:

• Soft tissue sarcoma is a rare cancer with limited treatment options.
• Epirubicin is an anthracycline chemotherapy agent used in various cancers.

Purpose of the Study:

• To determine the maximum-tolerated dose (MTD) of epirubicin in advanced soft tissue sarcoma.
• To evaluate the clinical efficacy and safety of epirubicin in this patient population.

Main Methods:

• A dose-escalation study involving 61 patients with advanced soft tissue sarcoma.
• Patients received epirubicin at doses of 140, 160, or 180 mg/m(2) every 3 weeks.
• Dose-limiting toxicity (DLT) was monitored to establish the MTD.

Main Results:

• The overall response rate was 44%, with a dose-response relationship observed (P=.02).
• Median response duration, time to progression, and overall survival were 10, 8, and 15 months, respectively.
• Myelosuppression, particularly grade 3/4 neutropenia (79%), was the most common toxicity.

Conclusions:

• The MTD of epirubicin was determined to be 180 mg/m(2).
• A dose of 160 mg/m(2) every 3 weeks with hematopoietic support is recommended for clinical use.
• Single high-dose epirubicin demonstrates efficacy as first-line treatment for advanced soft tissue sarcoma.